Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 12:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 78 matching trials from the live ClinicalTrials.gov search.
Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 30 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
iobenguane I 131
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

MCT for the Harvard/UCSF ROBIN Center

NCT06000787
Conditions
Glioma, Childhood Brainstem, Neuroblastoma
Interventions
External beam radiotherapy, 131I-Metaiodobenzylguanidine (MIBG)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Conditions
Neuroblastoma
Interventions
irinotecan hydrochloride, vincristine sulfate, iobenguane I 131
Drug · Radiation
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Completed No phase listed Observational Accepts healthy volunteers

Use of MIBG Scan Images in PVC Ablations

NCT02279030
Conditions
Premature Ventricular Contractions
Interventions
MIBG nuclear scan
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Congestive Heart Failure
Interventions
I-123 mIBG
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Neuroendocrine Tumors
Interventions
131-I MIBG and 111-In pentetreotide, 131-I MIBG and In-111 DOTATATE
Other
Lead sponsor
David Bushnell
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Iowa City, Iowa
Conditions
Neuroendocrine Tumors, Metastases, Neoplasm
Interventions
I-131 Metaiodobenzylguanidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions
Lutathera, Azedra
Drug
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Conditions
Neuroblastoma
Interventions
Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 29 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace Iobenguane I131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
3
States / cities
Iowa City, Iowa • Philadelphia, Pennsylvania • Houston, Texas
Conditions
Congestive Heart Failure
Interventions
123 iodine metaiodobenzylguanidine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Heart Failure, Congestive
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Interventions
131I-MIBG, 131-MIBG + Vorinostat
Drug
Lead sponsor
Jubilant DraxImage Inc.
Industry
Eligibility
1 Year and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
21
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 17 more
Conditions
Neuroblastoma
Interventions
External beam radiotherapy, proton beam RT
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Months to 18 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Recurrent Neuroblastoma
Interventions
hu14.18-IL2 fusion protein, isotretinoin, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
71
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 62 more
Conditions
Post-menopause
Interventions
Study Procedures
Other
Lead sponsor
Emory University
Other
Eligibility
45 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia
Conditions
Neuroblastoma
Interventions
Nivolumab, Ch14.18/CHO
Drug
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Other
Eligibility
1 Year to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Neuroblastoma
Interventions
Ultratrace Iobenguane I 131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Conditions
Neuroblastoma
Interventions
Hu3F8 With GM-CSF
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Results available

MIBG With Dinutuximab +/- Vorinostat

NCT03332667
Conditions
Neuroblastoma
Interventions
131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide
Radiation · Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more